Future Pharma - Challenges & Trends MES Process & Minds Conference Berlin, Germany, September 2015
|
|
- Whitney Henderson
- 6 years ago
- Views:
Transcription
1 Future Pharma - Challenges & Trends MES Process & Minds Conference Berlin, Germany, September 2015 (PhD)
2 Agenda Key challenges facing the Pharmaceutical Industry 1. Delivering shareholder/stakeholder value 2. Moderate growth business environment 3. R&D productivity 4. Increased M&A activities 5. Rising risks and loss of trust Selected Manufacturing and Technology Trends Summary of major trends: How could Future Pharma look like? Conclusion 1
3 1. Delivering Shareholder/Stakeholder Value the pharmaceutical industry has performed disappointingly over the last 5-10 years relative to other industries both in Europe and US 2
4 Factors influencing revenues, earnings and finally shareholder/stakeholder value Positives Strong growth in Emerging Markets Aging populations Willingness of payors to support innovation Improved efficiencies and operating margins Influenza pandemics Negatives Increasing speed of product competition Price reductions and rebates Higher regulatory hurdles, fewer product approvals Declining R&D productivity Increased clinical trial demands Increased legal settlements M&A activity is adding complexity whilst rarely generating better returns 3
5 Emerging Markets are growing more rapidly than pharma s Emerging core markets markets are in growing the US and more Europe rapidly than our core markets in the US and Europe Sales growth, CAGR 10% 8% 7% 3% Emerging markets US Europe World wide 9 PEM J Reinhardt 15 October 2014 Business Use Only 4
6 Todays Emerging Markets will represent 50% of the Healthcare Market in
7 Aging population and people with multiple diseases Cancer One person in three will have cancer Heart Disease 1 person dies from CVD every 33 seconds Brain Disorders 20% aged with Alzheimer s disease 900 million people in Asia to move from poverty to middle class in 2020 by 2030 the number of people >65 will - increase 51% in developed world - increase 140% in developing world almost half of lifetime healthcare expenditure is made after age 65 6
8 Increasing speed and intensity of product competition the average time a medicine is the only drug available in its therapeutic class declined dramatically from more than 10 years in the 1970s to less than 2 years by
9 2. Moderate growth business environment Global pharmaceutical sales surpassed 1 trillion $ in but CAGR has reduced and Pharma has become a more normal business with +3-6% growth 8
10 Global margins will come under pressure due to lower margins in EM Changing Geographic Contribution to Global Pre-R&D Operating Profit Region % 2010 global revenues Revenues ($bn) Est. Pre-R&D margin Pre-R&D op. profit ($bn) 19% 12% 21% 48% % 21% 16% 42% 2015 E 21% 30% 13% 36% 2020 E Other EM EU US US 36% % 200 EU 24% % 88 EM 18% % 51 Other 22% % 75 Total 100% % 415 $856 Pre-R&D Profit Margins Pressured due to Emerging Markets Pre-R&D Margin: 48% Pre-R&D $1'081 Margin: 44% $1'318 Pre-R&D Margin: 43% Revenue growth : +54% $415 $474 $566 Ops. profit growth : +36% 2010 E Revenues 2015 E Pre-R&D op. Profit 2020 E
11 3. R&D productivity rising costs and constant output level resulting in exponential decline in R&D productivity despite major advances in basic science 10
12 Number of FDA NME/BLA approvals and first-world launches /15 may be special as 11 NMEs were indicated within oncology of which seven received orphan drug status 67% of the first launches were specialty drugs indicated for the treatment of diseases such as cancer, HCV, eye disorders and other rare diseases 11
13 4. Increased M&A activities 12
14 Total deal value and deal volume by deal size and quarter 13
15 5. Rising risks and loss of trust Rising scientific risk Rising political risk Rising legal risk Loss of trust 14
16 Rising scientific risk Simultaneous development of new drugs in the same class in several companies Need to demonstrate value of a new drug early in the development process Personalised medicine based on biomarkers will replace trial-and-error approach: if no suitable biomarker can be found risk of non-approval with Health Authorities or low prices Biological variability will result in benefit for only a subset of patients Biomarker-based prediction of treatment response will allow selection of patients Examples: Trastuzumab (Herceptin, breasts cancer); Cetuximab (Erbitux, CR/HN cancer) Biomarkers are an opportunity for Diagnostic companies 15
17 Rising political risk Pressure from governments to reduce costs of medicines and chronic treatments will continue as Pharma Industry is cash rich Staying close to governmental thinking will be critical especially in Emerging Markets (local manufacturing, create jobs in health sector, affordable prices etc) 16
18 Rising legal risk there is a rapid increase of legal cases since
19 Loss of trust Perception that Pharma puts commercial goals above the interests of governments, payors, doctors and patients Investors remain sceptical of the longer term value due to the R&D pipeline disappointments Generally sceptical audience due to - integrity of commercial practices, - golden parachutes for top-executives - Warning Letters and product withdrawels 18
20 Agenda Key challenges facing the Pharmaceutical Industry 1. Delivering shareholder/stakeholder value 2. Moderate growth business environment 3. R&D productivity 4. Increased M&A activities 5. Rising risks and loss of trust Selected Manufacturing and Technology Trends Summary of major trends: How could Future Pharma look like? Conclusion 19
21 Selected Manufacturing and Technology Trends Productivity improvements Flexible Manufacturing in Biotech Biosimilars Industry 4.0 and Factory of the Future 20
22 Selected Manufacturing and Technology Trends Productivity improvements Operational Excellence and Lean Six Sigma will become the way of living To adress: operations/shopfloor management systems behavioural change Standardisation of process/unit operations most powerful on shopfloor optimisation Footprint optimisation will continue Leverage Corporate Procurement Benchmark with peers 21
23 Selected Manufacturing and Technology Trends Flexible Manufacturing in Biotech Classical biomanufacturing ( stainless steel cathedral ) is capital intensive, has long construction lead time, is fixed costs dominated and mostly single product Single Use Systems(SUS) or disposable technology has high flexibility, saves time, better matches output /demand, needs less space, 50% lower capital investment SUS mainly suitable for smaller quantities and therefore ideal to transfer biotech to Emerging Markets 22
24 Selected Manufacturing and Technology Trends Biosimilars Biosimilars are similar, not identical to their reference products 23
25 Numerous patent expirations of biologics will fuel market growth in biosimilars USD 89 bn of originator sales to expire until 2020 Sales USD billions 2010, based on year of US patent expiration Worldwide sales of expiring biologics APPROXIMATION Number of products Total Top product 3 Novo- Bene-FIX En- Epo-gen Ritu Seven brel -xan Lantus Humira Tysabri Avastin Herceptin Lucen-tis 1 Analysis does only include products with available sales and patent expiry information in Evaluate 2 Products only counted if sales reported in database 3 According to sales in 2010 Source: Evaluate
26 Biosimilars players are diverse and numerous 25
27 Selected Manufacturing and Technology Trends Industry 4.0 and Factory of the Future 26
28 The evolution to Industry 4.0 in production 27
29 Readiness check for EU countries Source: Roland Berger 28
30 Some ideas with regard to the smart Pharma- Factory of the Future We will have miniaturised processors, storage units, sensors and transmitters embedded in various types of machines and unfinished products New software for structuring data flows around a manufacturing facility Intelligent use of accurate and timely data to achieve consistent product quality, agility and validation transparency to satisfy regulatory pressures True integration of technology/process and systems by e.g. connection of QbD with production set limits, adjust when OOS release online by using PAT (Process Analytical Technology) faster change over times, frequent use of single use systems (SUS) 29
31 Some ideas with regard to the smart Pharma- Factory of the Future (cont.) We will have virtual systems and simulation tools for processes and projects We will see more continuous manufacturing in Pharma MES can be one key building block to drive these objectives a fully flexible system with open interfaces for virtual simulation fully validatable and regulatory compliant 30
32 For me the main challenges are Involve regulatory agencies (e.g. FDA) early enough in the Industry 4.0 discussion and already ongoing development in the industry Industry needs to help agencies to learn, to get them up to speed and ultimately to trust the Cyber Physical Systems- approach Industry needs to build-in auditing functionality for agencies so they can verify compliance Demonstrate the benefit and competitive advantage for a pharma company by embarking to the Industry 4.0 journey 31
33 Agenda Key challenges facing the Pharmaceutical Industry 1. Delivering shareholder/stakeholder value 2. Moderate growth business environment 3. R&D productivity 4. Increased M&A activities 5. Rising risks and loss of trust Selected Manufacturing and Technology Trends Summary of major trends: How could Future Pharma look like? Conclusion 32
34 Summary of major trends: How could Future Pharma look like? Trends Aging population with increasing healthcare needs Consequences /Options Persistent medical need especially in chronic diseases Emerging Markets will drive the growth of the pharma industry Portfolio- and project decisions based on EM requirements Rising costs and pressure on healthcare industry Increasing pressure on margins and drive to increase efficiency Strong demand on product value by regulatory agencies and payors Higher risk in R&D leading to increasing need for focused resources cont. 33
35 Summary of major trends: How could Future Pharma look like? Trends From product mindset to value mindset Pharma industry is lagging social media (blog, facebook, twitter) More strategic partnerships and acquisitions will continue Moving from selling drugs to enabling health outcomes Impact of «Industry 4.0» currently in Pharma underestimated Consequences/Options Cultural change in executives and staff Accelerate development and integration of social media and mobile-health policy Products and services complementing the traditional pharma portfolio will move into the focus New partnerships with IT-, retail- and financial companies IT companies need to customise value proposition for pharma clients 34
36 A vision of Future Pharma generating value is emerging 35
37 Conclusion Predicting the future is a risky business but we know that demand for health treatments will be huge A possible way forward for the Pharma Industry: 1. Strive for achieving breakthrough innovation 2. Strengthen position in non-mature Emerging Markets 3. Transform business model beyond a purely R&D driven approach 4. Embark on the journey of Industry 4.0 now! we are privileged to work in an exiting business! 36
38 Thank you for your attention! References: Contact: Future Pharma KPMG, 2011 Dr. Pharma X.0? Dr. J. Reinhardt, June 2012 Chemin des Macherettes 28 BioPharma 2020 GE Healthcare Life Sciences, Bougy-Villars Roland Berger Think Act, March 2014 Switzerland PwC - Deal Practice, May hanns_erle@yahoo.com Phone:
Margins of pharmaceutical companies are continuing to decline the future lies in new ecosystems
Karin Mateu Media Relations Tel.: +41 (0) 58 286 44 09 karin.mateu@ch.ey.com Margins of pharmaceutical companies are continuing to decline the future lies in new ecosystems Glaxo is leading the way in
More informationFocused pharma engineering
Focused pharma engineering When change is the only constant, are you up to speed? Welcome to the new pharma reality A major shift has taken place in the world of pharma manufacturing. The days when delivering
More informationJefferies 2016 Healthcare Conference. June 8, 2016
Jefferies 2016 Healthcare Conference June 8, 2016 Safe Harbor This presentation contains forward looking statements which are made pursuant to the safe harbor provisions of Section 27A of the Securities
More informationBetter Portfolio Decisions through Predictive Analytics
Better Portfolio Decisions through Predictive Analytics Speakers Jamie Munro, Global Practice Leader, Portfolio & Licensing, Clarivate Analytics Karthik Subramanian, Competitive Intelligence & Clinical
More informationBiotechnology Certificate New Technologies For Health
Weekly Barometer 25 janvier 2012 Biotechnology Certificate New Technologies For Health April 2017 ATONRÂ PARTNERS SA 12, Rue Pierre Fatio 1204 GENEVA SWITZERLAND - Tel: + 41 22 310 15 01 http://www.atonra.ch
More informationInvestor Overview Presentation ADVANCING LIFE SCIENCE TOGETHER
Investor Overview Presentation ADVANCING LIFE SCIENCE TOGETHER Forward-Looking Statement Disclaimer In order to take advantage of the safe harbor provisions of the private securities litigation reform
More informationDrugs, medical progress,
Drugs, medical progress, and the road ahead Scott Gottlieb, MD Resident Fellow The American Enterprise Institute Page 1 The Pharmaceutical Industry s Market Global Pharmaceutical Sales, by Region (in billions
More informationCommerzbank German Investment Seminar 2012
Commerzbank German Investment Seminar 2012 Matthias Zachert Chief Financial Officer New York, January 11, 2012 Agenda 1 The Merck Group 2 Key strengths 3 Unlocking value 4 Financials 5 Summary 2 Merck
More informationCheuvreux German Corporate Conference 2012
Cheuvreux German Corporate Conference 2012 Matthias Zachert Chief Financial Officer Frankfurt, January 17, 2012 Agenda 1 The Merck Group 2 Key strengths 3 Unlocking value 4 Financials 5 Summary 2 Merck
More informationBiotechnology Certificate New Technologies For Health
Weekly Barometer 25 janvier 2012 Biotechnology Certificate New Technologies For Health January 2018 ATONRÂ PARTNERS SA 12, Rue Pierre Fatio 1204 GENEVA SWITZERLAND - Tel: + 41 22 310 15 01 http://www.atonra.ch
More informationRoche: adapting to the changing environment. Severin Schwan, CEO Roche Group London, 15 September 2010
Roche: adapting to the changing environment Severin Schwan, CEO Roche Group London, 15 September 2010 This presentation contains certain forward-looking statements. These forward-looking statements may
More informationJefferies 2014 Global Healthcare Conference June 3, 2014 NYSE: Q
Jefferies 2014 Global Healthcare Conference June 3, 2014 NYSE: Q Copyright 2013 Quintiles Forward Looking Statements and Use of Non-GAAP Financial Measures This presentation contains forward-looking statements
More informationInnovation and Sustainability: An integrated approach
Innovation and Sustainability: An integrated approach Karl Mahler Head of Investor Relations Dianne Young Sustainability Communications Swiss Sustainability Leaders SRI Conference Zurich, 4 October 2013
More informationHelping unlock growth opportunities worldwide
Helping unlock growth opportunities worldwide A trusted partner for high-stakes decisions While scientific and technological advances fuel new business opportunities, the cost of bringing each new product
More informationUniversity of Connecticut Student Managed Fund 2018 Analyst Report. Jonathan Stryjek & Michael Pehota
University of Connecticut Student Managed Fund 2018 Analyst Report Jonathan Stryjek & Michael Pehota Table of Contents 3 Report Highlights 4 Business Overview 5 Industry Overview and Competitive Positioning
More informationICON plc. JP Morgan 33 rd Annual Healthcare Conference. Mr Ciaran Murray, Chief Executive Officer, ICON Plc 13 TH Jan 2015
ICON plc JP Morgan 33 rd Annual Healthcare Conference Mr Ciaran Murray, Chief Executive Officer, ICON Plc 13 TH Jan 2015 Forward Looking Statements Certain statements in today s presentation will be forward
More informationCapital Market Day June 12, 2012
Capital Market Day 2012 June 12, 2012 Product Segments IV Drugs John Ducker Member of the Management Board President Region North America Capital Market Day Fresenius Kabi, June 12, 2012 Agenda 1 2 3 4
More informationPharma. Vision. The first single view of the risk and reward of the R&D landscape
The first single view of the risk and reward of the R&D landscape We re proud and excited to introduce the latest stage of evolution for our flagship product, Evaluate. Evaluate has been at the forefront
More information34 th Annual J.P. Morgan Healthcare Conference
34 th Annual J.P. Morgan Healthcare Conference Vincent A. Forlenza Chairman, Chief Executive Officer and President January 13, 2016 Forward-Looking Statements These materials include forward-looking statements
More informationAlmac Overview.
Almac Overview www.almacgroup.com 2 Welcome to Almac 3 Who is Almac? Almac is a world leading drug development & commercial services company; providing an expanding array of innovative solutions worldwide
More informationEU support for Health Research from FP6 to FP7
EU support for Health Research from FP6 to FP7 Stéphane Hogan Head of Biotechnology Unit Directorate for Health Research DG Research - European Commission Valencia - 15 September 2006 EU research programmes
More informationAbout the Healthcare Strategic Analysis Team Geographic specific reports: Global issue reports: 1. About This Report Chapter structure Executive
About the Healthcare Strategic Analysis Team Geographic specific reports: Global issue reports: 1. About This Report Chapter structure Executive summary Licensing trends overview Evolving trends in the
More informationValuing Healthcare Biotechnology in Europe: EuropaBio s perspective
Valuing Healthcare Biotechnology in Europe: EuropaBio s perspective The healthcare biotechnology sector The healthcare biotechnology sector includes bioscience based enterprises, which create and deliver
More informationJohan Christenson MD; PhD Partner Farmasidagene 2014 Oslo
Johan Christenson MD; PhD Partner Farmasidagene 2014 Oslo 1 HealthCap Focuses on Breakthrough Therapeutics Significant resource base Partners with profound sector experience Six MD PhD s Extensive network
More informationIntroduction to IMI. Pierre Meulien Executive Director Innovative Medicines Initiative
Introduction to IMI Pierre Meulien Executive Director Innovative Medicines Initiative What is the Innovative Medicines Initiative? EU funding goes to: - universities - SMEs - patient groups etc 2.5 bn
More informationNews For Immediate Release
News For Immediate Release Contact: Gary Gatyas IMS Institute for Healthcare Informatics (610) 244-2600 ggatyas@us.imshealth.com IMS Study Forecasts Rebound in Global Spending on Medicines, Reaching Nearly
More informationPharma. Vision. The first single view of the risk and reward of the R&D landscape
The first single view of the risk and reward of the R&D landscape We re proud and excited to introduce the latest stage of evolution for our flagship product, EvaluatePharma. Alex Karle CEO, Evaluate Evaluate
More informationPrecision Medicine & Health Insurance Business Model Disruption? A Data& Evidence perspective
Precision Medicine & Health Insurance Business Model Disruption? A Data& Evidence perspective December 12 th, 2017 Dr. Tim Wintermantel Real World Insights Lead, Switzerland Copyright 2017 IQVIA. All rights
More informationTALENT STRATEGY AN INTEGRAL PART OF BUSINESS STRATEGY AT GENERALI
TALENT STRATEGY AN INTEGRAL PART OF BUSINESS STRATEGY AT GENERALI BERLIN, 21MAY 2015 Christina Anagnostopoulou Generali Group Talent Management GENERALI S CONCEPTUAL FRAMEWORK Diagnostic People Strategy
More informationACRUX PRESENTS AT BIOSHARES BIOTECH SUMMIT
ACRUX (ACR) - ASX ANNOUNCEMENT 24 JULY 2017 ACRUX PRESENTS AT BIOSHARES BIOTECH SUMMIT Acrux (ASX: ACR) today announced that CEO and Managing Director, Michael Kotsanis presented at the 2017 Bioshares
More informationCapital Markets Day 2016 Commercial Transformation growing faster than the market through differentiation. Gérard Kuperfarb, Growth & Innovation
Capital Markets Day 2016 Commercial Transformation growing faster than the market through differentiation Gérard Kuperfarb, Growth & Innovation Commercial Excellence through differentiation, commercial
More informationICON plc. 10th Jan Ciaran Murray CEO Steve Cutler CEO Designate. JP Morgan 35TH Annual Healthcare
ICON plc Ciaran Murray CEO Steve Cutler CEO Designate JP Morgan 35TH Annual Healthcare 10th Jan 2017 Forward Looking Statement Certain statements will be forward looking statements. Actual results may
More informationMaximizing Market Access: THE 5 MOST CRITICAL QUESTIONS TO ASK WHEN LAUNCHING A SPECIALTY DRUGS
Maximizing Market Access: THE 5 MOST CRITICAL QUESTIONS TO ASK WHEN LAUNCHING A SPECIALTY DRUGS by Jan Nielsen, division president, Access & Patient Support Are You Asking the Right Questions? We ve all
More informationLEVERAGING OUR BIOLOGICS EXPERTISE IN BIOSIMILARS SCOTT FORAKER VICE PRESIDENT AND GENERAL MANAGER, BIOSIMILARS
LEVERAGING OUR BIOLOGICS EXPERTISE IN BIOSIMILARS SCOTT FORAKER VICE PRESIDENT AND GENERAL MANAGER, BIOSIMILARS SAFE HARBOR STATEMENT This presentation contains forward-looking statements that are based
More informationJefferies 2018 Global Healthcare Conference. June 7, 2018
Jefferies 2018 Global Healthcare Conference June 7, 2018 Forward-Looking Statements Statements in this presentation regarding the future financial and operating results, outlook, growth, prospects, business
More informationBiopharmaceuticals Investor & Analyst Day
Adequate picture Biopharmaceuticals Investor & Analyst Day Strategic perspective on Merck KGaA, Darmstadt, Germany Karl-Ludwig Kley CEO Darmstadt, Germany September 18, 2014 Disclaimer Remarks All comparative
More informationTo meet the challenge of providing safe, cost-effective medicines for the world s largest
An Executive Summary Biopharma in China: New Initiatives, New Opportunities To meet the challenge of providing safe, cost-effective medicines for the world s largest population, the government of China
More informationUBS 2007 Global Life Sciences Conference. September 24, 2007
UBS 2007 Global Life Sciences Conference September 24, 2007 Safe Harbor This presentation contains "forward-looking" statements within the meaning of Section 27A of the Securities Act of 1933 and Section
More informationStrategic vision of Pharma Market
Strategic vision of Pharma Market Evolution 2012-2016 ACIP Presentation, Paris January 30, 2013 Introduction This presentation draws strategic orientations for pharma companies considering the expected
More informationThe Future of Market Access A FirstWord ExpertViews Dossier Report
AM PL E PA G ES S A G ES S A FirstWord ExpertViews Dossier Report Published Copyright 2016 Doctor s Guide Publishing Limited All rights reserved. No part of this publication may be reproduced or used in
More informationLeading domestic players in India s pharmaceutical market in 2015
THE INDIAN PHARMACEUTICAL MARKET LEADING DOMESTIC COMPANIES 2015 Leading domestic players in India s pharmaceutical market in 2015 1 Executive Summary 1.1 Executive Summary 1.2 Research and Analysis Methods
More informationBank of America Merrill Lynch Healthcare Conference. September 13, 2013
Bank of America Merrill Lynch Healthcare Conference September 13, 2013 Safe Harbor Statement This presentation contains forward-looking statements that are based on management s current expectations and
More informationThe digital change constant
Dr. Horst J. Kayser Boston, September 08, 2015 The digital change constant siemens.com Siemens Digitalization enables our customers to convert threats into opportunities Siemens customers facing challenges
More informationClinical Trials: Facts and Trends. Dr Nik Nikitin. Founder/Director, Russlan Clinical. ManxBioMed Annual Bio Business Conference 10 th December 2013
Clinical Trials: Facts and Trends Dr Nik Nikitin Founder/Director, Russlan Clinical What is a clinical trial? A clinical trial is a research study in human volunteers to answer specific health questions
More informationDrivers for Continuous Tablet Manufacturing in Pharmaceutical Industry
Drivers for Continuous Tablet Manufacturing in Pharmaceutical Industry Satu Lakio PhD (pharm.), Adj. Prof. Industrialisation and product life cycle management Orion Pharma 29th Annual Symposium of the
More informationAccelerating the pace and impact of digital transformation
RESEARCH REPORT Accelerating the pace and impact of digital transformation How the consumer goods and retail organizations view the digital agenda A Harvard Business Review Analytic Services study in association
More informationBioProcess Technology Consultants, Inc. Helping Clients De-Risk Biopharmaceutical Development Since 1994
, Inc. Helping Clients De-Risk Biopharmaceutical Development Since 1994 Who We Are The biopharmaceutical and biotherapeutic development experts We are a team of results-oriented professionals assisting
More informationInsights into the Evolving Pricing & Market Access Environment
Insights into the Evolving Pricing & Market Access Environment UBC Global Market Access Survey July 2012 JULY 2012 GLOBAL MARKET ACCESS SURVEY UBC s Global Market Access Survey: Setting the Stage For those
More information2009 INVESTOR DAY. BioPharmaceuticals. Ken Frank President BioPharmaceuticals December 17, Sustainable, Profitable Growth
2009 INVESTOR DAY BioPharmaceuticals Ken Frank President BioPharmaceuticals December 17, 2009 Sustainable, Profitable Growth Life Sciences FY 2009 Total Sales $2,329.2 (amounts shown in millions) BioPharmaceuticals
More information2015 Investor Meeting
2015 Investor Meeting New York City December 4, 2015 Safe Harbor Except for historical information, the matters discussed in this presentation may constitute forward-looking statements that involve risks
More informationPharmaceutical Marketing in Turbulent Times - Developing innovative approaches to face new challenges
Pharmaceutical Marketing in Turbulent Times - Developing innovative approaches to face new challenges Vienna, 7 November, 2011 Current context and challenges Demand for healthcare is rising Aging population,
More informationTeva Pharmaceutical Industries Ltd. J.P. Morgan Healthcare Conference. Kåre Schultz President and CEO January 7, 2019
Teva Pharmaceutical Industries Ltd. J.P. Morgan Healthcare Conference Kåre Schultz President and CEO January 7, 2019 Cautionary Note Regarding Forward-Looking Statements 2 This presentation contains forward-looking
More informationThe NHS approach to personalised medicine in respiratory disease. Professor Sue Chief Scientific Officer for England
The NHS approach to personalised medicine in respiratory disease Professor Sue Hill @CSOSue Chief Scientific Officer for England Jul 2017 Genomics is probably the biggest breakthrough in the last 50 years.
More informationISPE: Pharma Industry Outlook
ISPE: Pharma Industry Outlook ANDREW D. SKIBO Head of Global Biologics Operations & Global Engineering MedImmune/AstraZeneca Chairman, ISPE Board of Directors October 7, 2015 Linking Past ISPE Drivers
More informationMoving from volume to value in the generic business model
Moving from volume to value in the generic business model CPhI Pre-connect conference Frankfurt 23rd October 2017 Copyright 2016 QuintilesIMS. All rights reserved. Key drivers to 2021 Global growth moderating
More informationFINANCIAL PERSPECTIVES
FINANCIAL PERSPECTIVES M³ - Meet Merck Management Marcus Kuhnert, CFO Darmstadt December 10, 2015 Disclaimer Cautionary Note Regarding Forward-Looking Statements This communication may include forward-looking
More informationL A B O R M A R K E T B R I E F I N G S S E R I E S
L A B O R M A R K E T B R I E F I N G S S E R I E S LABOR MARKET INFORMATION FOR RESEARCHERS THE LIFE SCIENCE AND PHARMACEUTICALS SECTOR IN EUROPE L I F E S C I E N C E A N D P H A R M A C E U T I C A
More informationJP Morgan Healthcare Conference Stefan Oschmann Head of Pharma. San Francisco, January 9, 2012
JP Morgan Healthcare Conference Stefan Oschmann Head of Pharma San Francisco, January 9, 2012 Disclaimer Remarks All comparative figures relate to the corresponding last year s period. From 2007 the Generics
More informationBiopharma in the coming era of connected health
14 Health-care focus: Perspective Celia Johnson Biopharma in the coming era of connected health Disruptive technologies are already reshaping the industry. Here s how executives can meet the resulting
More informationGlobal Life Sciences BPO Market to be Worth USD 596 Billion by 2019: Transparency Market Research
Transparency Market Research Global Life Sciences BPO Market to be Worth USD 596 Billion by 2019: Transparency Market Research Buy Now Request Sample Published Date: April 2014 Single User License: US
More informationHuntsworth Plc. Capital Markets Day
Huntsworth Plc Capital Markets Day 1 Agenda 1:45 Intro Paul Taaffe / Neil Jones 2:05 apothecom - An introduction to medical affairs 2:30 TCEG The changing nature of engagement 2:55 Refreshments 3:25 Evoke
More informationPrescription Medicines: Costs in Context
Prescription Medicines: Costs in Context 2018 We are in a new era of medicine where breakthrough science is transforming care with innovative treatment approaches... Then Now Medicines made of chemical
More informationGenomics Market Share, Size, Analysis, Growth, Trends and Forecasts to 2024 Hexa Research
Genomics Market Share, Size, Analysis, Growth, Trends and Forecasts to 2024 Hexa Research " Increasing usage of novel genomics techniques and tools, evaluation of their benefit to patient outcome and focusing
More informationBiotech Showcase 2016
1 Biotech Showcase 2016 Our Value Proposition Advancing broad product pipeline of biosimilars and next generation antibody therapeutics Proven track record in superior quality, efficient R&D and manufacturing
More informationFDA Driving Biomedical Product Innovation
FDA Driving Biomedical Product Innovation Vicki Seyfert-Margolis, Ph.D. Senior Advisor, Science Innovation and Policy Office of the Commissioner November 12, 2012 1 FDA Mission FDA is charged with protecting
More informationBio-Pharma: China A Look at The FUTURE: 4 th & 5 th Generation Global Strategies
Global Strategy Global Challenges Executable Solutions Bio-Pharma: China 2010-2020 A Look at The FUTURE: 4 th & 5 th Generation Global Strategies France Houdard Managing Director January 2010 Table of
More informationEnterprise Performance Management in the Pharmaceutical Industry. kpmg.co.uk
Enterprise Performance Management in the Pharmaceutical Industry kpmg.co.uk Are your performance management processes, metrics and tools prepared for tomorrow s strategic challenges in pharmaceuticals?
More informationGE Growth Strategy. Business Development & Organic Growth. Hwang Soo President of GE Korea Feb. 12, 2008
GE Growth Strategy Business Development & Organic Growth Hwang Soo President of GE Korea Feb. 12, 2008 This is GE We are World s Most Admired Company The only company listed in the Dow Jones Industrial
More informationEmployment in the biopharma industry grew almost 5 percent in 2014, the last full year for which we have data. This is the highest annual growth rate
Thank you, Mr. Chairman, and members of the committee. I m Sarah MacDonald, Executive Vice President at MassBio, the life sciences trade association now representing over 700 member organizations. First,
More informationPharma EXPO 6 9 November 2016 Chicago, IL
DESIGN TO VALUE: An End-to-end Lifecycle Methodology, Enabling Customer-centric, High-quality Products, Made Efficiently and Reliably Susan Neadle Senior Director Design to Value & Product Quality Management
More informationFebruary 25, 2019 (Monday) 8:30-16:30 Hrs BioPark Visit (Only for Invitees)
February 25, 2019 (Monday) 8:30-16:30 Hrs BioPark Visit (Only for Invitees) 18:00-19:30 Hrs Inauguration of the 16 th BioAsia Convention Presentation of Genome Valley Excellence Award 19:30-20:00 Hrs Inauguration
More informationSustainable Profitable Growth through Innovation. Pascal Soriot Chief Operating Officer Roche Pharmaceuticals
1 Sustainable Profitable Growth through Innovation Pascal Soriot Chief Operating Officer Roche Pharmaceuticals 2 Q1 2009: A good start into the year 3 Q1 2010: High growth for both divisions Well above
More informationBringing a successful partnership to the next level
Bringing a successful partnership to the next level Basle, 21 July 2008 This presentation contains certain forward-looking statements. These forward-looking statements may be identified by words such as
More informationUniversal Biosensors, Inc.
Universal Biosensors, Inc. ARBN 121 559 993 UBS Australian Healthcare Conference November 2011 1 Important Disclaimer This presentation is intended to provide a general outline only and is not intended
More information2012 Healthcare (Pharmaceutical) Industry Perspective
2012 Healthcare (Pharmaceutical) Industry Perspective In keeping with our tradition, we pause to reflect on the critical issues the pharmaceutical industry will face in 2012 and how life sciences companies
More informationInvestor Presentation RBC Capital Markets Global Healthcare Conference February 22, 2017
Investor Presentation 2017 RBC Capital Markets Global Healthcare Conference February 22, 2017 Forward-Looking Statements This document may contain forward-looking statements within the meaning of the Private
More informationStrategy resets to patient outcomes. The state of life sciences
Strategy resets to patient outcomes The state of life sciences New innovative products, even at a high cost, can be a great deal for society and the health care system if they cure a chronic disease. Expensive
More informationJ.P. Morgan Healthcare Conference January 10, 2018
J.P. Morgan Healthcare Conference January 10, 2018 Safe Harbor This presentation is intended to be disclosure through methods reasonably designed to provide broad, non-exclusionary distribution to the
More informationArtificial Intelligence in Life Sciences: The Formula for Pharma Success Across the Drug Lifecycle
Volume XX, Issue 60 Artificial Intelligence in Life Sciences: The Formula for Pharma Success Across the Drug Lifecycle Artificial intelligence (AI) has the potential to transform the pharmaceutical industry.
More informationAccelerating the pace and impact of digital transformation
RESEARCH REPORT Accelerating the pace and impact of digital transformation How the manufacturing organizations view the digital agenda A Harvard Business Review Analytics Services study in association
More informationAnnual General Meeting Roche Holding Ltd 14 March 2017
Annual General Meeting Roche Holding Ltd 14 March 2017 Address by Christoph Franz Chairman of the Board of Directors (Check against delivery) Address Christoph Franz Page 2/10 Dear Shareholders, Ladies
More informationEmerging Trends in Regulatory Outsourcing WHITE PAPER.
WHITE PAPER www.makrocare.com/consulting You are not alone in the quest for bringing your products to market and improve the quality of the life for millions! MakroCare brings you the insight on how a
More informationKRISANI BIO SCIENCES PVT. LTD.
KRISANI BIO SCIENCES PVT. LTD. Flat B2, 2 nd Floor, Suryateja Apartments, Hindi Nagar, Punjagutta, Hyderabad, Telangana 500078. Email: kkr@krisanibio.com. URL: www.krisanibio.com Contact Number: +91 98494
More informationThe value and specificity of the rare disease business model
The value and specificity of the rare disease business model The point of view from a dedicated orphan drug company Philippe Van Holle International Chairman, Celgene 6th European Conference on Rare Diseases
More informationList of contributors List of abbreviations. 1 The business of healthcare innovation in the Wharton School curriculum 1
Contents List of contributors List of abbreviations page viii xiv xvii 1 The business of healthcare innovation in the Wharton School curriculum 1 Lawton Robert Burns 2 The pharmaceutical sector: rebooted
More informationMANAGING MATURE PRODUCT PORTFOLIOS - KEY CHALLENGES AND BENEFITS
WHITEPAPER MANAGING MATURE PRODUCT PORTFOLIOS - KEY CHALLENGES AND BENEFITS Dr. Constanze Burkhardt Senior Director, Strategic Outsourcing constanze.burkhardt@pharmalex.com Constanze has worked for PharmaLex
More informationHow can regulatory affairs drive greater value for the patient and for the business?
How can regulatory affairs drive greater value for the patient and for the business? Exploring the key considerations How do you combat the rising costs of regulatory affairs? What s the best operating
More informationDeveloping Drugs for Rare Diseases: Patient Advocacy s Perspective. Kristina Bowyer Executive Director, Patient Advocacy
Developing Drugs for Rare Diseases: Patient Advocacy s Perspective Kristina Bowyer Executive Director, Patient Advocacy February 5, 2018 An Advocacy Perspective Why develop drugs for Rare Disease? What
More informationTRUSTED GLOBAL LEADER
TRUSTED GLOBAL LEADER FULL YEAR RESULTS YEAR ENDED 30 JUNE 2017 OVERVIEW FY17 Highlights Gross profit* STRONG FULL YEAR PERFORMANCE FY15 53.7M ALL OPERATIONS CONTRIBUTING TO GOOD LEVELS OF ORGANIC GROWTH
More informationJefferies 2015 Global Healthcare Conference June 3, 2015
Jefferies 2015 Global Healthcare Conference June 3, 2015 Forward-Looking Statements This document may contain forward-looking statements within the meaning of the Private Securities Litigation Reform Act
More informationWHILE A SMALL NUMBER OF PEOPLE ARE SUFFERING FROM A SINGLE RARE DISEASE, 350 MILLION PEOPLE WORLDWIDE ARE SUFFERING FROM RARE DISEASES.
June 2017 WHILE A SMALL NUMBER OF PEOPLE ARE SUFFERING FROM A SINGLE RARE DISEASE, 350 MILLION PEOPLE WORLDWIDE ARE SUFFERING FROM RARE DISEASES. 3rd most populous country 50% of affected are children
More informationTXT e-solutions. Corporate Presentation March 2015
TXT e-solutions Corporate Presentation March 2015 2014: Another year of Growth Revenues: 55.9 m (+6.3%), 57% from Int l Operations EBIT: 5.5 m (+10%) Cash Flow from Op. 9.3% of Revenues NFP: 8.5m (+ Treasury
More informationIntelligent energy and data solutions for tomorrow's world. Investor Presentation Q1 2018
Intelligent energy and data solutions for tomorrow's world Investor Presentation Q1 2018 A global leader in wiring systems and cable technology LEONI at a glance Industrial Solutions Business mix (in %
More informationehealth-strategien im Wettbewerb: Erfolgsfaktor oder schmückendes Beiwerk? ehealth Kongress Darmstadt, 17 Oktober 2014
ehealth-strategien im Wettbewerb: Erfolgsfaktor oder schmückendes Beiwerk? ehealth Kongress Darmstadt, 17 Oktober 2014 Health care is in the middle of a perfect storm Changing demographics Unmet needs
More informationShivom, the global Genomics-Blockchain Ecosystem The Next Era of Genomics and Healthcare
Shivom, the global Genomics-Blockchain Ecosystem The Next Era of Genomics and Healthcare The world of healthcare is changing - with two revolutionary technologies, genomics and blockchain poised to significantly
More informationPrescription Medicines: Costs in Context
Prescription Medicines: Costs in Context 2017 We are in a new era of medicine where breakthrough science is transforming care with innovative treatment approaches... Then Now Medicines made of chemical
More informationGlobal Biosimilar Market Trends & Opportunities: 2015 Edition
Global Biosimilar Market Trends & Opportunities: 2015 Edition Global Biosimilar Market Trends & Opportunities: 2015 Edition BioPortfolio has been marketing business and market research reports from selected
More informationJefferies 2017 Global Healthcare Conference. June 7, 2017
Jefferies 2017 Global Healthcare Conference June 7, 2017 Forward-Looking Statements This document may contain forward-looking statements within the meaning of the Private Securities Litigation Reform Act
More informationYASHAJIT SAHA & ABHISHEK SHARMA, SUBJECT MATTER EXPERTS, RESEARCH & ANALYTICS ADVANCED ANALYTICS: A REMEDY FOR COMMERCIAL SUCCESS IN PHARMA.
YASHAJIT SAHA & ABHISHEK SHARMA, SUBJECT MATTER EXPERTS, RESEARCH & ANALYTICS ADVANCED ANALYTICS: A REMEDY FOR COMMERCIAL SUCCESS IN PHARMA wns wns ADVANCED ANALYTICS: A REMEDY FOR COMMERCIAL SUCCESS IN
More informationAusbiotech Biotech Invest Summit
ASX code: LBT lbtinnovations.com Ausbiotech Biotech Invest Summit 3 December 2014 Lusia Guthrie, CEO Disclaimer This document contains certain forward-looking statements that involve risks and uncertainties.
More information